Cardiovascular disease (CVD) continues to be the primary cause of mortality among individuals with diabetes, demonstrating the complex metabolic, renal, and vascular relationships that define the cardio-kidney-metabolic (CKM) continuum. As Malaysia experiences increasing prevalence of obesity and type 2 diabetes (T2D), the burden of cardiovascular (CV) complications continues to rise. This highlights the necessity for a novel clinical perspective, one that acknowledges metabolic dysfunction as an integral aspect of a systemic disorder, thus necessitating urgent, coordinated intervention. In this second of a series of articles championing awareness on the CKM concept, Datin Dr Ong Mei Lin explains the necessity for cardiologists to assume a more proactive role in managing diabetes at CKM Stage 2 and discusses how evidence-based treatments, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide, can influence long-term CV outcomes.